Active Litigation
Ocaliva Lawsuit Facts
TorHoerman Law is actively accepting claims for the Ocaliva Lawsuit.
Active Litigation
TorHoerman Law is actively accepting claims for the Ocaliva Lawsuit.
No Ocaliva lawsuit settlement amounts or verdicts have been publicly reported.
Because the litigation is still developing, any settlement estimates are based on comparisons to similar pharmaceutical injury cases involving severe organ damage.
These projections reflect the seriousness of the alleged injuries being investigated, including liver failure, transplant-related complications, and death.
TorHoerman Law is currently reviewing potential Ocaliva lawsuit claims and speaking with individuals and families who believe the drug may have contributed to severe liver injury or loss.

Ocaliva was prescribed to treat primary biliary cholangitis (PBC), but the growing focus of this litigation is whether the drug exposed some patients harmed by it to serious liver injury and other severe complications.
No public settlement amounts or verdicts have been reported, which means any discussion of value remains an early projection rather than a record of actual payouts.
Based on the severity of injuries being alleged in these cases, potential Ocaliva lawsuit settlement amounts could fall within a broad range of roughly $75,000 to $250,000+, with higher values more likely in claims involving catastrophic outcomes.
Much may depend on whether the evidence shows worsening liver function after use of the drug, the extent of the person’s medical treatment, and whether the claim involves permanent damage or loss of life.
Cases involving liver decompensation, transplant evaluation, or long-term complications may be viewed differently than claims involving shorter-term injury without lasting impairment.
Potential value may also turn on how clearly medical records connect the drug to liver injury risks that allegedly materialized after treatment began.
In the most severe cases, families may be exploring a wrongful death lawsuit rather than an individual injury claim, which can change both the damages analysis and the legal issues involved.
This page explains what may affect projected compensation, what lawyers are looking at when filing Ocaliva lawsuits, and why TorHoerman Law is speaking with individuals and families about potential claims.
If you or a loved one took Ocaliva and later experienced severe liver damage or other serious health complications, you may be eligible to file an Ocaliva lawsuit.
Contact TorHoerman Law for a free consultation.
You can also use the chat feature on this page to find out if you qualify for an Ocaliva lawsuit.
At this stage, the estimated Ocaliva lawsuit settlement range remains broad, with early projections falling around $75,000 to $250,000+ depending on the facts of the case.
That range is not based on any reported Ocaliva payouts, but on the types of injuries now being examined and the way severe pharmaceutical injury claims are often valued in early litigation.
Cases involving serious liver damage, repeated hospitalization, or documented liver decline may be viewed very differently from claims involving more limited complications.
Potential value may also depend on whether the evidence suggests the drug contributed to accelerating liver disease progression beyond what physicians would have otherwise expected.
The highest-value claims may involve catastrophic outcomes, including transplant-related injuries and fatal liver failure.
The sections below break that range down further by injury severity, medical proof, and the long-term impact on the person or family bringing the claim.
Some projected Ocaliva claims may fall into a lower settlement tier when the reported injury involves impaired liver function without transplant, liver failure, or another catastrophic outcome.
In this context, the estimated range may begin around $50,000 to $100,000, though no public Ocaliva settlements have been reported and any figure remains an early projection only.
These cases may involve less serious liver complications that still required medical attention, medication changes, or follow-up care after concerns about Ocaliva’s risks emerged.
Even in moderate claims, case value may depend heavily on whether medical experts can connect the person’s decline to the drug rather than the expected course of disease in PBC patients.
This category does not mean the injury was minor, only that the long-term damage, financial losses, and overall medical burden may be more limited than in higher-value claims.

Medical records and expert review may focus on factors such as the following:
Some projected Ocaliva claims may fall into a higher tier when the evidence points to significant liver injury rather than a more limited change in liver function.
In this category, an estimated range of $100,000 to $200,000 may apply in early projections, though no public Ocaliva settlements have been reported and these figures remain speculative.
These cases may involve a rapid decline in liver health, more substantial treatment needs, and a stronger argument that the drug contributed to worsening complications beyond the expected course of disease.
The value of these claims may increase when the records show more serious disruption affecting the liver and bile ducts, particularly in cases involving life-threatening liver complications.

Medical records and case review may focus on factors such as the following:
This projected range still depends on medical proof, causation evidence, and the person’s long-term outcome.
Claims involving transplant, permanent disability, or death would likely be evaluated in a higher category.
Claims involving Ocaliva users who required a liver transplant may fall into one of the highest projected settlement tiers because transplantation reflects a profound and life-altering medical outcome.
In this category, an early estimated range of $150,000 to $200,000+ may apply, though no public Ocaliva settlements have been reported and any figure remains a preliminary projection only.
These cases often involve acute liver failure, severe hospitalization, and long-term medical consequences that extend far beyond the initial injury.

Potential value may also rise where the records suggest worsening liver injury after treatment began, especially when the person’s condition progressed toward permanent organ damage.
In some cases, the central dispute may be whether the transplant became necessary because of the expected course of advanced liver disease or because Ocaliva contributed to an additional and avoidable decline.
That question will likely depend on detailed medical records, treating physicians, and expert review of how the injury developed over time.
Wrongful death claims may represent the highest projected tier in this litigation because they involve the loss of a person who was prescribed Ocaliva and later allegedly developed liver injury that proved fatal.
In this category, early projections may begin at $200,000+, though no public Ocaliva settlements or verdicts have been reported and any estimate remains speculative.
These cases may involve allegations that the drug contributed to fatal liver failure, transplant-related complications, or another irreversible decline that ended in death.
The projected value of these claims may depend on the available medical evidence, the age and circumstances of the person who died, and the financial and personal losses suffered by surviving family members.
Some of the most complex cases may include liver transplant death claims, where the medical timeline involves both severe intervention and an alleged fatal outcome.

Case review in wrongful death claims may focus on factors such as the following:
These cases are often fact-intensive and may require careful review of the full treatment history, including liver function testing, hospital records, and end-of-life care.
They may also involve legal questions about who has the right to bring the claim and what categories of damages may be available under the applicable state law.
Because of that, wrongful death projections should be presented cautiously and tied to the specific facts of the case rather than any assumed average payout.
Any discussion of Ocaliva lawsuit settlement projections should be read with caution because the litigation remains in an early stage and no public settlement history exists.
These figures are not guarantees, promises, or average settlement amounts.
They are only broad estimates meant to help readers understand how claim value may differ based on injury severity, medical proof, and long-term losses.
Ocaliva claims are still developing, and case values may change as litigation progresses through the legal process.
That is especially true in pharmaceutical cases, where case strength often turns on expert review, disputed causation, and evolving evidence.
For that reason, responsible defective drug attorneys do not present projected values as fixed outcomes.

Important points to keep in mind include the following:
Ocaliva (obeticholic acid) was a prescription medication approved to treat primary biliary cholangitis, or PBC, in certain adults, but its regulatory history became increasingly tied to reports of severe liver-related complications.
FDA said in December 2024 that it had identified cases of serious liver injury in some Ocaliva patients without cirrhosis and advised close monitoring for worsening liver function.
In 2025, Ocaliva was withdrawn from the U.S. market after years of escalating safety concerns, and Intercept states the drug was officially removed from the U.S. commercial market on November 14, 2025.
FDA’s withdrawal record says the postmarketing trial did not verify clinical benefit and identified an excess of liver transplants and deaths among certain Ocaliva-treated PBC patients, which is central to current scrutiny over the drug’s liver impairment risks.
The current lawsuit investigation focuses on whether Intercept Pharmaceuticals gave inadequate warnings and whether there was a failure to warn patients and healthcare providers about the severity of those risks as evidence developed.

Claim investigations now commonly center on allegations involving liver failure, transplant, hepatic decompensation, and death after Ocaliva use.
As of early 2026, there have been no publicly announced settlements or jury verdicts involving Ocaliva (obeticholic acid), which means the litigation is still at a very early stage.
If filings continue to grow, Ocaliva cases could eventually be consolidated into multidistrict litigation, though no mature MDL settlement framework exists at this point.
Ocaliva (obeticholic acid) was approved by the US Food and Drug Administration (FDA) in 2016 as a second-line therapy for certain patients with primary biliary cholangitis who did not respond adequately to ursodeoxycholic acid.
Over the following years, the agency issued multiple drug safety communication notices describing serious liver-related adverse effects associated with the medication.
Early warnings focused on incorrect dosing in patients with advanced cirrhosis, which FDA linked to cases of liver failure and death.
Subsequent safety reviews expanded those concerns to include severe liver injury in some patients without cirrhosis.
FDA eventually added a boxed warning and later restricted the drug’s use in patients with advanced liver disease after reports of worsening liver injury.
Post-marketing data also showed higher rates of liver transplant and death among some Ocaliva users compared with placebo in a required clinical study.
Regulatory developments involving Ocaliva include:
FDA communications, clinical trial findings, and post-marketing reports documented serious liver injury associated with the medication.
These regulatory actions form part of the factual record being examined in ongoing Ocaliva lawsuit investigations.
No publicly announced settlements or jury verdicts have been reported in lawsuits involving Ocaliva (obeticholic acid).
You may qualify for the Ocaliva lawsuit if you took the drug and later developed serious liver-related complications that were not expected from the ordinary course of your condition alone.
Many claims now under review involve allegations of liver failure, hepatic decompensation, transplant-related injury, or death after Ocaliva use.
A potential case may be stronger when medical records show a decline after treatment began, especially where physicians documented abnormal labs, hospitalization, or other warning signs of worsening liver function.
Eligibility may also depend on whether the evidence suggests the drug contributed to the injury rather than only reflecting the underlying progression of primary biliary cholangitis.
People who required emergency treatment, transplant evaluation, or long-term follow-up care may have claims worth reviewing more closely.

Families who lost a loved one after Ocaliva treatment may also have grounds to pursue compensation through a wrongful death claim, depending on the facts and the applicable law.
Because these cases are medically complex, qualification often turns on treatment history, timing, and expert review of causation.
TorHoerman Law is speaking with individuals and families to evaluate whether the facts support filing an Ocaliva lawsuit.
Gathering evidence for an Ocaliva lawsuit starts with building a clear record of how the medication was prescribed, how symptoms developed, and how the resulting injuries were diagnosed and treated.
The first step in pursuing an Ocaliva lawsuit is to collect the relevant medical records, prescription history, and treatment timeline.
Attorneys typically review that documentation to assess whether Ocaliva may have contributed to liver decline or other serious health complications, rather than the outcome reflecting only the expected course of the underlying disease.
The stronger and more complete the file, the easier it becomes to build a reliable timeline and show when the injury emerged, how it progressed, and what treatment followed.
That includes records showing whether the patient reported unexpected or worsening symptoms, since patients were repeatedly advised to alert their providers so monitoring and intervention could be arranged.
Strong evidence also helps show the seriousness of the injury, the treatment burden, and the losses connected to the claim.
Our firm can help collect and review these materials as part of the intake process.

Evidence in an Ocaliva lawsuit may include the following:
Damages are the categories of loss a plaintiff may seek to recover in a lawsuit after an injury allegedly caused by a drug.
In an Ocaliva case, lawyers assess damages by reviewing the person’s medical history, the severity of the liver-related injury, the treatment required, and the effect the condition had on daily life and long-term health.
That analysis usually begins with direct financial losses such as medical expenses and lost wages, then expands to less easily measured harm such as physical pain, emotional distress, and reduced quality of life.
Lawyers also look closely at symptoms that may reflect the burden of the injury, including weakness, repeated hospitalization, and extreme fatigue that interferes with ordinary activities.
In more serious cases, damages may also involve death-related losses and, in some circumstances, allegations supporting punitive damages.
The goal is to build a damages model that reflects both the economic impact of the injury and the human consequences behind claims for pain and suffering.

Potential damages in an Ocaliva lawsuit may include the following:
Ocaliva lawsuits are still in the early stages, but the growing body of regulatory findings and patient reports has led to increased scrutiny of the drug’s safety profile.
Individuals who experienced serious liver complications after taking Ocaliva may have questions about whether the medication contributed to their injury and what legal options may exist.
These cases often require a careful review of prescription history, medical records, and the progression of liver-related symptoms over time.
TorHoerman Law is reviewing potential Ocaliva claims involving liver injury, transplant-related complications, and wrongful death.

If you or a loved one experienced serious health complications after taking Ocaliva, speaking with an attorney may help determine whether the circumstances support a legal claim.
Contact us today for a free consultation.
You can also use the chat feature on this page for a free, confidential case evaluation.
Ocaliva was first approved by the FDA in 2016, under the accelerated approval pathway, as a second-line treatment for adults with primary biliary cholangitis, which meant the company still had to complete post-market studies to confirm the drug’s safety and clinical benefit.
In February 2018, the FDA added a boxed warning after linking Ocaliva to serious liver injury, especially in patients with pre-existing liver conditions.
Later safety reviews became more serious, with FDA stating that post-marketing data showed higher rates of liver transplant and death in some Ocaliva-treated patients than in the placebo group.
In November 2024, Intercept disclosed that FDA had issued a Complete Response Letter declining full approval of Ocaliva in its current form.
In Europe, regulators also moved against the drug, and the EMA says Ocaliva’s conditional marketing authorization was revoked after concluding that its benefits no longer outweighed its risks.
Ocaliva was then withdrawn from the U.S. market on September 11, 2025, following FDA pressure tied to those safety concerns and the failed postmarketing showing.
Evidence in an Ocaliva lawsuit helps show when the drug was prescribed, when symptoms began, how the condition changed over time, and what losses followed.
In a medically complex case involving liver injury, lawyers usually look for records that can connect the treatment timeline to the reported decline and rule out other explanations as much as possible.
Useful evidence may include:
The more complete the documentation, the easier it is to build a clear timeline and evaluate whether the facts support filing an Ocaliva lawsuit.
FDA approval does not prevent later lawsuits when evidence emerges that a drug may carry serious risks that were not fully tested, fully understood, or clearly communicated at the time of approval.
In the case of Ocaliva, post-marketing data reportedly showed that even some patients without existing liver cirrhosis experienced liver transplant or death at rates higher than placebo, which raised deeper concerns about the drug’s safety profile.
Ocaliva was later withdrawn from the U.S. market in September 2025 after FDA concluded that its risks outweighed its benefits.
Current lawsuits and investigations allege that Intercept Pharmaceuticals failed to properly test Ocaliva and failed to warn about its dangers as the evidence developed.
Some critics have also argued that important risk updates were not communicated clearly enough and that critical safety information was buried in label changes rather than presented in a way that fully alerted doctors and patients.
A prior investor class action against Intercept was dismissed in March 2022, but that case involved securities claims by shareholders, not personal injury claims by patients and families alleging liver injury, transplant, or death.
FDA and Intercept told patients not to stop or change treatment on their own, but to speak with their healthcare providers about next steps and alternative treatment options.
FDA’s December 2024 safety communication also told healthcare professionals to monitor liver tests frequently in patients taking Ocaliva so worsening liver function could be identified early and the drug could be discontinued when appropriate.
Intercept’s withdrawal FAQ later said the September 2025 withdrawal was not a contamination recall and that patients were given a transition period to consult their providers before the product left the U.S. commercial market on November 14, 2025.
Patients and healthcare providers were generally told to do the following:

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Ocaliva Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.